Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology

Volumn 28, Issue 10, 2017, Pages 2451-2457

  Martinez Marti, A ^a,b,c   Felip, Enriqueta ^a,b,c   Matito, J ^b   Mereu, E ^d,e   Navarro, A ^a,b   Cedres S ^a,b   Pardo, N ^a,b,c   de Castro, A Martinez ^a,b   Remon, J ^a,b   Miquel, J M ^b   Guillaumet Adkins, A ^d,e   Nadal, E ^f,g   Rodriguez Esteban, G ^d,e   Arques O ^b   Fasani, R ^b   Nuciforo, P ^b   Heyn, H ^d,e   Villanueva, A ^f,h   Palmer, H G ^b   Vivancos, A ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d BARCELONA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^h Xenopat SL   (Spain)

Author keywords

Acquired resistance; EGFR; Intratumor plasticity; MET; NSCLC; T790M

Indexed keywords

AFATINIB; CAPMATINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAZARTINIB; OSIMERTINIB; PROTEIN P53; ROCILETINIB; ANTINEOPLASTIC AGENT; CISPLATIN; EGFR PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MET PROTEIN, HUMAN; PEMETREXED; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TRIAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BIOPSY; BRAIN METASTASIS; BRAIN SURGERY; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MET GENE; METASTASIS POTENTIAL; METASTATIC LUNG ADENOCARCINOMA; MONOTHERAPY; MOUSE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SMOKING HABIT; TUMOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; LUNG TUMOR; NUDE MOUSE; RANDOMIZATION; SECONDARY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PEMETREXED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85030527025     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx396     Document Type: Article

References (32)

1. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388
2. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246
3. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334
4. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26
5. Cross DA, Ashton SE, Ghiorghiu S et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-1061
6. Walter AO, Sjin RT, Haringsma HJ et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC. Cancer Discov 2013; 3: 1404-1415
7. Park K, Han JY, Kim DW et al. 190TiP: ELUXA 1: phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). J Thorac Oncol 2016; 11(4 Suppl): S139
8. Jia Y, Juarez J, Li J et al. EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Res 2016; 76(6): 1591-1602
9. Jänne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-1699
10. Sequist LV, Soria JC, Camidge DR. Update to rociletinib data with the RECIST confirmed response rate. N Engl J Med 2016; 374: 2296-2297
11. Thress K, Paweletz CP, Felip E et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21: 560-562
12. Chabon JJ, Simmons AD, Lovejoy AF et al. Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 2016; 7: 11815
13. Bersanelli M, Minari R, Bordi P et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol 2016; 11(10): e121-e123
14. Planchard D, Loriot Y, André F et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 2015; 26: 2073-2078
15. Eberlein CA, Stetson D, Markovets AA et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res 2015; 12: 2489-2500
16. Ortiz-Cuaran S, Scheffler M, Plenker D et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res 2016; 22(19): 4837-4847
17. Schildhaus HU, Schultheis AM, Rüschoff J et al. MET amplification status in therapy-naïve adeno-and squamous cell carcinomas of the lung. Clin Cancer Res 2015; 21(4): 907-915
18. Rüschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25: 637-650
19. Scheffler M, Merkelbach-Bruse S, Bos M et al. Spatial tumor heterogeneity in lung cancer with acquired epidermal growth factor receptor-tyrosine kinase inhibitor resistance: targeting high-level MET-amplification and EGFR T790M mutation occurring at different sites in the same patient. J Thorac Oncol 2015; 10(6): e40-e43
20. John T, Kohler D, PintilieMet al. The ability to formprimary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2011; 17: 134-141
21. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumor xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004; 40: 802-820
22. Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 2015; 15: 451-452
23. Fichtner I, Rolff J, Soong R et al. Establishment of patient-derived nonsmall cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008; 14: 6456-6468
24. Hindson BJ, Ness KD, Masquelier DA et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83: 8604-8610
25. Jaitin DA, Kenigsberg E, Keren-Shaul H et al. Massively parallel singlecell RNA-seq for marker-free decomposition of tissues into cell types. Science 2014; 343: 776-779
26. Paul F, Arkin Y, Giladi A et al. Transcriptional heterogeneity and lineage commitment in myeloid progenitors. Cell 2015; 163: 1663-1677
27. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-550
28. Nanjo S, Arai S, WangWet al. MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer. Mol Cancer Ther 2017; 16(3): 506-515
29. Yonesaka K, Kudo K, Nishida S et al. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget 2015; 6: 33602-33611
30. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536
31. Diaz LA, Jr, Williams RT, Kinde I et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-540
32. Fan J, Salathia N, Liu R et al. Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. Nat Methods 2016; 13: 241-244